GlassScriptPhysician profile
Jacob C Rube
NPI 1477963601
$12,167.17
in general payments reported to CMS, 2019-2025
25 companies · $6,951 in 2025
The $6,951 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $124 · 2021: $1,380 · 2022: $1,481 · 2023: $191 · 2024: $1,642 · 2025: $6,951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,434 · Travel and Lodging: $1,814 · Food and Beverage: $987 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,434.17 |
| Travel and Lodging | $1,814.28 |
| Food and Beverage | $986.79 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $550.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $5,164.63 | 2025 | |
| Janssen Scientific Affairs, LLC | $2,061.82 | 2021-2025 | |
| Argenx US, INC. | $1,425.00 | 2022 | |
| Ucb, INC. | $696.55 | 2023-2025 | Rystiggo |
| Amgen INC. | $689.92 | 2025 | Uplizna |
| Vertex Pharmaceuticals Incorporated | $536.67 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $392.85 | 2019-2025 | |
| Biogen, INC. | $337.92 | 2019-2025 | Tysabri |
| Emd Serono, INC. | $251.38 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $150.00 | 2021 | |
| Abbvie INC. | $104.32 | 2024 | |
| Genzyme Corporation | $90.99 | 2019 | |
| Tg Therapeutics, INC. | $84.82 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $60.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.91 | 2024-2025 | Hyqvia |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $36.89 | 2022-2024 | Enspryng, Ocrevus |
| Electronic Waveform Lab, INC. | $17.17 | 2025 | |
| Aquestive Therapeutics, INC. | $13.33 | 2019 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Rube listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.